This website is currently under complete revision, also to demonstrate new positive clinical data (November 2022).
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ORYX is the exclusive licensee of premier cancer immunotherapy substances from the German Cancer Research Center (DKFZ) and the University of Heidelberg. The Company has established close collaborations with DKFZ, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Nordwest Hospital Frankfurt, Darmstadt Clinic and leading experts as well as an outstanding network of scientific and clinical advisors.